Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Non-cash Items (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Non-cash Items readings, the most recent being $6.1 million for Q1 2026.

  • On a quarterly basis, Non-cash Items fell 20.94% to $6.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.1 million, a 20.94% decrease, with the full-year FY2025 number at $6.2 million, down 19.68% from a year prior.
  • Non-cash Items hit $6.1 million in Q1 2026 for Kiniksa Pharmaceuticals International, roughly flat from $6.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $62.3 million in Q4 2024 to a low of $5.1 million in Q1 2022.
  • Median Non-cash Items over the past 5 years was $7.0 million (2023), compared with a mean of $14.2 million.
  • Biggest five-year swings in Non-cash Items: soared 118.33% in 2022 and later crashed 90.11% in 2025.
  • Kiniksa Pharmaceuticals International's Non-cash Items stood at $32.6 million in 2022, then soared by 67.47% to $54.7 million in 2023, then increased by 14.05% to $62.3 million in 2024, then crashed by 90.11% to $6.2 million in 2025, then decreased by 0.42% to $6.1 million in 2026.
  • The last three reported values for Non-cash Items were $6.1 million (Q1 2026), $6.2 million (Q4 2025), and $6.6 million (Q3 2025) per Business Quant data.